 (CHEST 1997; 111:419-26) 
In a recent trial,8 we have shown that early supple¬ mental IV immunoglobulin (Ig) treatment improves disease severity and may improve prognosis in prospec¬ tively Acute Physiology and Chronic Health Evaluation (APACHE II)9 score-identified high-risk postcardiac surgical patients, compared to a historical control pop¬ ulation equivalent in patient characteristics and disease severity (Fig 1, left) . This (Fig 1, left) +Dosage on an arbitrary scale from 1 to 8 ("l"=dopamine^1 0 jig/kg/min; "8".adrenaline and noradrenaline and/or angiotensin, each >50 |xg/min).
arterial BP <60 mm Hg17 or need for vasopressor administration higher than 10 |ULg/kg/min dopamine. Ig levels were determined by nephelometric measurements in serum samples.
The main study end points were as follows: (1) (Fig 1, right) (Fig 2) . Both IgG and IgGMA treatment led to higher IgG levels that persisted until day 5. This increase in IgG serum levels was significant on day 2 for the IgG prepara¬ tion and on day 3 for the IgGMA therapy (Fig 2, left) Figure 2 , left, both preparations were similar in obtaining this rise in IgG levels, despite a lower standard dosage of the IgGMA preparation. The earlier peak in the IgG group was most likely due to the higher dosage administered on day 1 (see "Materials and Methods" section). Regarding serum IgM, expectedly, only the IgGMA preparation led to significantly increased levels (Fig 2, right) (Fig 1, left) (Fig 1, right) , similar to that encountered in a preceding Ig treat¬ ment study (Fig 1, left) and superior to the previously described historical control population (Fig 1, left) 
